We assisted a biopharmaceutical manufacturer with a limited distribution network oncology drug launch. The distribution strategy included third-party logistics providers, specialty drug distributors and specialty pharmacies. The manufacturer offered patient services through its network specialty pharmacies and hub. Bass, Berry & Sims provided holistic regulatory and contracting support for the launch which included, structuring the distribution and services strategy; guidance on the third party logistic provider and specialty distributor contracts; guidance related to the core and enhanced specialty pharmacy services required of network specialty pharmacies and the hub, such as patient adherence, quick start programs, bridge programs and data services; and drafting and assisting with the negotiation of the specialty pharmacy drug purchase agreements and services agreements.
Biopharmaceutical Manufacturer Launches a Limited Distribution Network Oncology Drug
You Also May Be Interested In:
We represented BioScrip, Inc. in its merger with Option Care Enterprises, Inc. The newly combined company, Option Care Health, Inc., emerges as the largest independent home and alternate site infusion services provider in the United States. Option Care Health’s common stock will be listed on the Nasdaq Global Select Market under the ticker symbol BIOS.
Served as lead healthcare regulatory counsel to Amazon (Nasdaq: AMZN) in its acquisition of PillPack
Represented a leading provider of 340B Drug Pricing Program services in its acquisition by a prescription benefit management subsidiary of a leading pharmacy healthcare provider